

**Date:** November 12, 2025

To,  
The Manager- Listing Department,  
**National Stock Exchange of India Limited,**  
Exchange Plaza, Plot No. C/1, Block-G,  
Bandra - Kurla Complex, Bandra (E),  
Mumbai - 400051

**SYMBOL: REMUS**

**Sub.: Intimation under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 - Notice of Postal ballot**

Dear Sir/Madam,

Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Listing Regulations"), as amended from time to time, please find attached herewith a copy of the Postal Ballot Notice, dated November 10, 2025, along with the Explanatory Statement ("Postal Ballot Notice"), dispatched today, for seeking the approval of the Members of Remus Pharmaceuticals Limited ("the Company") on item of Special Business as mentioned in the said Notice

1. Approval for Material Related Party Transaction between Espee Biopharma & Finechem LLC ("EBFL") with Rise Pharma LLC ("RPL") (Ordinary Resolution)

The schedule of events for the Postal Ballot is as given under:

|                                                                          |                                              |
|--------------------------------------------------------------------------|----------------------------------------------|
| <b>Cut-off date (for dispatch and e-voting)</b>                          | Friday, November 07, 2025                    |
| <b>Completion date of sending of Postal Ballot Notice through e-mail</b> | Wednesday, November 12, 2025                 |
| <b>E-voting start date/time</b>                                          | Saturday, November 15, 2025 (09:00 A.M. IST) |
| <b>E-voting end date/time</b>                                            | Monday, December 15, 2025 (05:00 P.M. IST)   |
| <b>Voting Results along with Scrutinizer's Report</b>                    | On or before Wednesday, December 17, 2025    |

The Postal Ballot Notice along with e-voting instructions has been made available on the website of the Company at [www.remuspharma.com](http://www.remuspharma.com).

You are requested to take the same on record.

Thanking you.

**For, Remus Pharmaceuticals Limited**

**Deval Patel**  
Company Secretary and Compliance Officer  
ICSI Membership No.: A60090

Encl: As Above

## **Remus Pharmaceuticals Limited**

**REGISTERED OFFICE:** 1101 to 1103, South Tower, One42, B/H Ashok Vatika, Nr. Jayantilal Park BRTS,  
Ambli Bopal Road, Ahmedabad-380054, Gujarat, India.  
P: 079 2999 9857

E. [remus@remuspharma.com](mailto:remus@remuspharma.com) | W. [www.remuspharma.com](http://www.remuspharma.com)  
GST NO: 24AAHCR4771P2ZQ | CIN NO: L24232GJ2015PLC084536



## REMUS PHARMACEUTICALS LIMITED

**Regd. Office:** 1101 to 1103, South Tower, One 42, B/H Ashok Vatika, Nr. Jayantilal Park BRTS, Ambli Bopal Road, Ahmedabad – 380 054, Gujarat

**Tel:** 079-2999 9857 | **CIN:** L24232GJ2015PLC084536

**Website:** [www.remuspharma.com](http://www.remuspharma.com) | **Email ID:** [cs@remuspharma.com](mailto:cs@remuspharma.com)

### NOTICE OF POSTAL BALLOT

*Pursuant to Sections 108 and 110 of the Companies Act, 2013 read with Rules 20 and 22 of Companies (Management and Administration) Rules, 2014*

Dear Member(s),

**NOTICE** is hereby given to the members of **Remus Pharmaceuticals Limited** (the “Company”) pursuant to the provisions of Sections 108, 110 and all other applicable provisions of the Companies Act, 2013 read with the Companies (Management and Administration) Rules, 2014 (collectively the “Act”, which shall include any statutory modifications, amendments or re-enactments thereto) read with General Circular Nos.14/2020 dated 8<sup>th</sup> April 2020, 17/2020 dated 13<sup>th</sup> April 2020, 22/2020 dated 15<sup>th</sup> June 2020, 33/2020 dated 28<sup>th</sup> September 2020, 39/2020 dated 31<sup>st</sup> December 2020, 10/2021 dated 23<sup>rd</sup> June 2021, 20/2021 dated 8<sup>th</sup> December 2021, 3/2022 dated 5<sup>th</sup> May 2022, 11/2022 dated 28<sup>th</sup> December 2022, 09/2023 dated 25<sup>th</sup> September, 2023, 09/2024 dated 19<sup>th</sup> September, 2024 and 03/2025 dated 22<sup>nd</sup> September, 2025 issued by the Ministry of Corporate Affairs, Government of India (the “MCA Circulars”), Secretarial Standard-2 on General Meetings (“SS-2”) issued by the Institute of Company Secretaries of India (as amended from time to time), Regulation 44 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (the “Listing Regulations”) and any other applicable law, rules and regulations (including any statutory modification(s) or re-enactment(s) thereof, for the time being in force), read with the equity listing agreement executed with the stock exchange on which the equity shares of the Company are listed, for seeking approval of the shareholders by way of ordinary resolution for matters as considered in the Resolution(s) appended below through postal ballot (“Postal Ballot”) by way of e-voting only.

Pursuant to Sections 102, 110 and other applicable provisions of the Act, the Explanatory Statement pertaining to the said Resolution setting out the material facts and related particulars is annexed hereto.

This Postal Ballot Notice is being sent in electronic form to those Members, whose names appear in the Register of Members/List of Beneficial Owners as on Friday, November 07, 2025 (‘Record Date’) as received from MUFG Intime India Private Limited (formerly known as Link Intime India Private Limited) (“MUFG Intime”), the Registrar and Share Transfer Agent (“RTA”) of the Company and whose e-mail addresses are registered with the Depositories (in case of electronic shareholding). In compliance with the provisions of Section 108 and Section 110 of the Act read with Rule 20 and 22 of the Rules, Regulation 44 of the Listing Regulations, and SS-2, the Company is pleased to provide e-voting facility to its Members, to enable them to cast their votes electronically. The detailed procedure with respect to e-voting is mentioned in this Notice.

The Company has engaged the services of MUFG Intime for facilitating e-voting. The Company has made necessary arrangements with RTA to enable the Members to register their e-mail address. Those Members who have not yet registered their e-mail address are requested to register the same by following the procedure set out in this Postal Ballot Notice.

The Board has appointed Mr. Tapan Shah, Practicing Company Secretary, (CP No. 2839/Membership No.: FCS4476) as the Scrutinizer (“Scrutinizer”) for conducting the Postal Ballot / e-voting process in a fair and transparent manner.

Members desiring to exercise their vote through the e-voting process are requested to carefully read the instructions indicated in this Notice and record their assent (FOR) or dissent (AGAINST) by following the procedure as stated in the Notes forming part of the Notice.

**The votes can be cast during the following voting period:**

| REMOTE E-VOTING STARTS                       | REMOTE E-VOTING ENDS ON                    |
|----------------------------------------------|--------------------------------------------|
| Saturday, November 15, 2025 at 9:00 AM (IST) | Monday, December 15, 2025 at 5:00 PM (IST) |

The e-voting facility will be disabled by MUFG Intime immediately thereafter and will not be allowed beyond the said date and time. The Scrutinizer will submit his report to the Chairman of the Company (the “Chairman”) or any other person authorized by the Chairman, and the result of the voting by Postal Ballot will be announced on or before Wednesday, December 17, 2025.

The results of the postal ballot (including voting through electronic means) along with the Scrutinizer’s report will be made available on the website of the Company at [www.remuspharma.com](http://www.remuspharma.com) and intimated to the stock exchange, where the shares of the Company are listed, on or before Wednesday, December 17, 2025.

The last date of e-voting, i.e., December 15, 2025, shall be the date on which the resolutions would be deemed to have been passed, if passed by the requisite majority.

## **Special Business**

### **ITEM NO. 1**

#### **APPROVAL FOR MATERIAL RELATED PARTY TRANSACTION BETWEEN ESPEE BIOPHARMA & FINECHEM LLC (“EBFL”) WITH RISE PHARMA LLC (“RPL”)**

To consider, and if thought fit, to pass, with or without modifications, the following resolution as an **Ordinary Resolution**:

“**RESOLVED THAT** pursuant to Regulations 2(1)(zc), 23(4) and other applicable regulations of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with Industry Standards on related party transactions notified by the SEBI (as amended till date), the applicable provisions of the Companies Act, 2013 read with the related rules framed thereunder (including any statutory modification(s) or reenactment(s) thereof for the time being in force) and other applicable laws/statutory provisions, if any, and pursuant to the Company’s Policy on Related Party Transactions and based on the approval of the Audit Committee and recommendation of the Board of Directors (hereinafter

referred to as the 'Board', which term shall be deemed to include any Committee constituted / empowered / to be constituted by the Board from time to time to exercise its powers conferred by this resolution), the consent of the Members be and is hereby accorded to the related party contract(s)/arrangement(s)/transaction(s) (whether by way of an individual transaction or transactions taken together or series of transactions or otherwise) as detailed in the Explanatory Statement, to be entered into and/or carried out and/or continued between related parties of Remus Pharmaceuticals Limited ('the Company') i.e. Espee Biopharma and Finechem LLC ("EBFL"), a step-down subsidiary of the Company and Rise Pharma LLC ("RPL"), on such terms and conditions as may be agreed between EBFL and RPL, for an aggregate value not exceeding INR 100 crore (Indian Rupees One Hundred Crores) during FY25-26, subject to such contract(s)/ arrangement(s)/transaction(s) being carried out at arm's length and in the ordinary course of business of EBFL and RPL;

**RESOLVED FURTHER THAT** the Board be and is hereby authorised to delegate all or any of the powers herein conferred, to any Director or Key Managerial Personnel or any other officer or the Authorised Representative of the Company, to do all such acts and take such steps, as may be considered necessary or expedient, to give effect to the aforesaid Resolution;

**RESOLVED FURTHER THAT** all actions taken by the Board, or any person so authorized by the Board, in connection with any matter referred to or contemplated in any of the foregoing Resolution, be and are hereby approved, ratified and confirmed in all respects; and

**RESOLVED FURTHER THAT** any Director or Company Secretary of the Company be and is hereby severally authorized to certify the true copy of this resolution and forward the same to any person or authority for their records and necessary action."

By order of the Board of Directors  
For & on behalf of **Remus Pharmaceuticals Limited**

**Deval Patel**  
Company Secretary & Compliance Officer  
ICSI Membership No.: A60090

**Place:** Ahmedabad  
**Date:** November 10, 2025

**Registered Office:**  
1101 to 1103, South Tower,  
One 42, B/H Ashok Vatika,  
Nr. Jayantilal Park BRTS,  
Ambli Bopal Road,  
Ahmedabad – 380 054, Gujarat

## NOTES:

1. The Explanatory Statement pursuant to Section 102 read with Section 110 of the Act and Rule 22 of the Rules setting out the material facts and reasons for the proposed Resolution of the Postal Ballot Notice is appended herein below for your consideration and forms part of this Notice.
2. In compliance with the provisions of Section 108 and Section 110 of the Act read with Rules 20 and 22 of the Rules, Regulation 44 of the Listing Regulations, SS-2 and the MCA Circulars, the Company is pleased to provide e-Voting facility to its Members, to enable them to cast their votes electronically. The Company has engaged the services of MUFG Intime India Private Limited (“MUFG Intime”) (formerly known as Link Intime India Private Limited), the Registrar and Share Transfer Agent of the Company (“RTA”) provide e-voting facilities to its members. The instructions for e-voting are annexed to this Notice.
3. The Notice is being sent to all the Members, whose names appear on the Register of Members/ List of Beneficial Owners as on Friday, November 07, 2025, as received from National Securities Depository Limited (“NSDL”) and Central Depository Services Limited (“CDSL”) (collectively referred to as “Depositories”). In compliance with the MCA Circulars, the Notice is being sent to Members only in electronic form to the e-mail addresses registered with their Depository Participants (in case of electronic shareholding)/the Company’s Registrar and Transfer Agent (in case of physical shareholding). Physical copies of the Notice are not being sent to the Members for this Postal Ballot. Therefore, those Members who have not yet registered their e-mail addresses are requested to get their e-mail addresses registered by following the procedure given in the e-voting instructions.
4. As per the MCA Circulars, physical copies of the Postal Ballot Notice, postal ballot forms and pre-paid business reply envelopes are not being sent to Members for this postal ballot. Members are requested to provide their assent or dissent through e-Voting only. The Company has engaged the services of MUFG Intime for providing e-Voting facility to its members.
5. A copy of the Postal Ballot Notice is available on the website of the Company at [www.remuspharma.com](http://www.remuspharma.com), website of the stock exchange i.e. National Stock Exchange of India Limited at [www.nseindia.com](http://www.nseindia.com) respectively and on the website of our e-Voting agency i.e. MUFG Intime at <https://instavote.linkintime.co.in/Home>.
6. All relevant documents referred to in the Postal Ballot Notice will also be available electronically for inspection, without any fee, to Members from the date of circulation of the Postal Ballot Notice up to the closure of the voting period. Members desirous of inspecting the documents referred to in the Notice or Statement may send their requests to [cs@remuspharma.com](mailto:cs@remuspharma.com) from their registered e-mail addresses mentioning their names, folio numbers/DP ID and Client ID.
7. To support the ‘Green Initiative’, Members who have not yet registered their email addresses are requested to register the same with their Depository Participants in case the shares are held by them in electronic form and with the Company in case the shares are held by them in physical form.
8. The voting rights of the Members shall be in proportion to their share of the paid-up equity share capital of the Company as on the Cut-Off Date i.e. Friday, November 07, 2025. Only those members whose names appear in the Register of Members / List of Beneficial Owners as on the Cut-off Date shall only be considered eligible for the purpose of e-Voting and those members would be able to cast their votes and convey their assent or dissent to the proposed resolution only through the e-Voting process. Any person who is not a Member as on the Cut-off date should treat this Postal Ballot Notice for information purpose only.

9. Members of the Company as on the Cut-Off Date (including those Members who may not have received this Notice due to non-registration of their e-mail addresses with the Company/RTA/Depositories) shall be entitled to vote in relation to the aforementioned resolution in accordance with the process specified in this Postal Ballot Notice. A Member cannot exercise his vote by proxy on a Postal Ballot.
10. The e-Voting details are as under:

|                                  |                                                                        |
|----------------------------------|------------------------------------------------------------------------|
| <b>Commencement of e-voting:</b> | Saturday, November 15, 2025 at 9:00 a.m. (IST)                         |
| <b>End of e-voting:</b>          | Monday, December 15, 2025 at 05:00 p.m. (IST)<br>(both days inclusive) |

During this period, members of the Company holding shares in physical or electronic form as on the Cut-Off Date may cast their vote electronically. The e-Voting will be blocked by MUFG Intime immediately thereafter and will not be allowed beyond the said date and time.

11. Members are requested to cast their vote through the e-Voting process not later than 5:00 p.m. IST on Monday, December 15, 2025, in order to be eligible for being considered, failing which it will be strictly considered that no vote has been received from the Member. Once the votes on the Resolution are casted by the Member, the Member shall not be allowed to change these subsequently.
12. The Board of Directors of the Company has appointed Mr. Tapan Shah, Practicing Company Secretary, (CP No. 2839/Membership No.: FCS4476) Address: 816-818, Anand Mangal – 3, Opp. Core House, Nr. Doctor House, Ellisbridge, Ahmedabad-380006 as the Scrutinizer to scrutinize the Postal Ballot through e-Voting process in a fair and transparent manner. He has communicated his willingness for such an appointment and will be available for the same.
13. The Scrutinizer will submit his report to the Chairman of the Company or such person as authorized, upon completion of scrutiny of the votes received through the e-voting platform, not later than Wednesday, December 17, 2025. The Chairman or any person so authorized by him, shall announce the results of the Postal Ballot on or before 05:00 p.m. (IST) Wednesday, December 17, 2025 in accordance with the regulatory provisions.
14. The Results declared along with the Scrutinizer's Report shall be placed on the Company's website [www.remuspharma.com](http://www.remuspharma.com) and on the website of RTA immediately after the result is declared by the Chairman or any other person authorized by him, and the same shall be communicated to the Stock Exchange, where the equity shares of the Company are listed.
15. The Resolution, if approved by the requisite majority through Postal Ballot, shall be deemed to have been passed on Monday, December 15, 2025 i.e., the last date specified for receipt of votes through the e-Voting process.

## PROCEDURE FOR E-VOTING:

In terms of SEBI circular no. SEBI/HO/CFD/PoD2/CIR/P/2023/120 dated July 11, 2023, Individual shareholders holding securities in demat mode are allowed to vote through their demat account maintained with Depositories and Depository Participants.

Shareholders are advised to update their mobile number and email Id correctly in their demat accounts to access e-Voting facility.

Login method for Individual shareholders holding securities in demat mode is given below:

## **Individual Shareholders holding securities in demat mode with NSDL**

### **METHOD 1 - NSDL IDeAS facility**

#### **Shareholders registered for IDeAS facility:**

- Visit URL: <https://eservices.nsdl.com> and click on “Beneficial Owner” icon under “IDeAS Login Section”.
- Click on “Beneficial Owner” icon under “IDeAS Login Section”.
- Post successful authentication, you will be able to see e-Voting services under Value added services section. Click on “Access to e-Voting” under e-Voting services.
- Click on “MUFG InTime” or “evoting link displayed alongside Company’s Name” and you will be redirected to InstaVote website for casting the vote during the remote e-voting period.

#### **Shareholders not registered for IDeAS facility:**

- To register, visit URL: <https://eservices.nsdl.com> and select “Register Online for IDeAS Portal” or click on <https://eservices.nsdl.com/SecureWeb/IdeasDirectReg.jsp>
- Enter 8-character DP ID, 8-digit Client ID, Mobile no, Verification code & click on “Submit”.
- Enter the last 4 digits of your bank account / generate ‘OTP’
- Post successful registration, user will be provided with Login ID and password. Follow steps given above in points (a-d).

Shareholders/ Members can also download NSDL Mobile App “NSDL Speede” facility by scanning the QR code mentioned below for seamless voting experience.



### **METHOD 2 - NSDL e-voting website**

- Visit URL: <https://www.evoting.nsdl.com>
- Click on the “Login” tab available under ‘Shareholder/Member’ section.
- Enter User ID (i.e., your sixteen-digit demat account number held with NSDL), Password/OTP and a Verification Code as shown on the screen.
- Post successful authentication, you will be re-directed to NSDL depository website wherein you will be able to see e-Voting services under Value added services. Click on “Access to e-Voting” under e-Voting services.
- Click on “MUFG InTime” or “evoting link displayed alongside Company’s Name” and you will be redirected to InstaVote website for casting the vote during the remote e-voting period.

### **METHOD 3 - NSDL OTP based login**

- Visit URL: <https://eservices.nsdl.com/SecureWeb/evoting/evotinglogin.jsp>
- Enter your 8 - character DP ID, 8 - digit Client Id, PAN, Verification code and generate OTP.
- Enter the OTP received on your registered email ID/ mobile number and click on login.
- Post successful authentication, you will be re-directed to NSDL depository website wherein you will be able to see e-Voting services under Value added services. Click on “Access to e-Voting” under e-Voting services.
- Click on “MUFG InTime” or “evoting link displayed alongside Company’s Name” and you will be redirected to InstaVote website for casting the vote during the remote e-voting period.



## **Individual Shareholders holding securities in demat mode with CDSL**

### **METHOD 1 – CDSL Easi/ Easiest facility:**

#### **Shareholders who have registered/ opted for CDSL Easi/ Easiest facility:**

- a) Visit URL: <https://web.cdslindia.com/myeasitoken/Home/Login> or [www.cdslindia.com](http://www.cdslindia.com) and Click on New System Myeasi Tab
- b) Enter existing username, Password & click on “Login”.
- c) Post successful authentication, user will be able to see e-voting option. The evoting option will have links of e-voting service providers i.e., MUFG InTime. Click on “MUFG InTime” or “evoting link displayed alongside Company’s Name” and you will be redirected to InstaVote website for casting the vote during the remote e-voting period.

#### **Shareholders registered for CDSL Easi/ Easiest facility:**

- a) To register, visit URL: <https://web.cdslindia.com/myeasitoken/Registration/EasiRegistration/> / <https://web.cdslindia.com/myeasitoken/Registration/EasiestRegistration>
- b) Proceed with updating the required fields for registration.
- c) Post successful registration, user will be provided username and password. Follow steps given above in points (a-c).

### **METHOD 2 - CDSL e-voting page**

- a) Visit URL: <https://www.cdslindia.com>
- b) Go to e-voting tab.
- c) Enter Demat Account Number (BO ID) and PAN No. and click on “Submit”.
- d) System will authenticate the user by sending OTP on registered Mobile and Email as recorded in Demat Account
- e) Post successful authentication, user will be able to see e-voting option. The evoting option will have links of e-voting service providers i.e., MUFG InTime. Click on “MUFG InTime” or “evoting link displayed alongside Company’s Name” and you will be redirected to InstaVote website for casting the vote during the remote e-voting period.

## **Individual Shareholders holding securities in demat mode with Depository Participant**

Individual shareholders can also login using the login credentials of your demat account through your depository participant registered with NSDL / CDSL for e-voting facility.

- a) Login to DP website
- b) After Successful login, user shall navigate through “e-voting” option.
- c) Click on e-voting option, user will be redirected to NSDL / CDSL Depository website after successful authentication, wherein user can see e-voting feature.
- d) Post successful authentication, click on “MUFG InTime” or “evoting link displayed alongside Company’s Name” and you will be redirected to InstaVote website for casting the vote during the remote e-voting period.

## **Login method for shareholders holding securities in physical mode / Non-Individual Shareholders holding securities in demat mode**

Shareholders holding shares in physical mode / Non-Individual Shareholders holding securities in demat mode as on the cut-off date for e-voting may register for InstaVote as under:



## STEP 1: LOGIN / SIGNUP to InstaVote

### Shareholders registered for INSTAVOTE facility:

a) Visit URL: <https://instavote.linkintime.co.in> & click on “**Login**” under ‘SHARE HOLDER’ tab.

b) Enter details as under:

- A. User ID: Enter User ID
- B. Password: Enter existing Password
- C. Enter Image Verification (CAPTCHA) Code
- D. Click “Submit”.

(Home page of e-voting will open.

Follow the process given under "Steps to cast vote for Resolutions")

|                   |                              |                                                                                                                |
|-------------------|------------------------------|----------------------------------------------------------------------------------------------------------------|
| InstaVote USER ID | NSDL                         | User ID is 8 Character DP ID followed by 8 Digit Client ID (e.g.IN123456) and 8 digit Client ID (eg.12345678). |
|                   | CDSL                         | User ID is 16 Digit Beneficiary ID.                                                                            |
|                   | Shares held in physical form | User ID is Event No + Folio no., registered with the Company                                                   |

### Shareholders not registered for INSTAVOTE facility:

a) Visit URL: <https://instavote.linkintime.co.in> & click on “**Sign Up**” under ‘SHARE HOLDER’ tab & register with details as under:

1. User ID: Enter User ID
2. PAN: Enter your 10-digit Permanent Account Number (PAN) (Shareholders who have not updated their PAN with the Depository Participant (DP)/ Company shall use the sequence number provided to you, if applicable.
3. DOB/DOI: Enter the Date of Birth (DOB) / Date of Incorporation (DOI) (As recorded with your DP/Company - in DD/MM/YYYY format)
4. Bank Account Number: Enter your Bank Account Number (last four digits), as recorded with your DP/Company.
  - o Shareholders holding shares in **NSDL form**, shall provide ‘D’ above
  - o Shareholders holding shares in **physical form** but have not recorded ‘C’ and ‘D’, shall provide their Folio number in ‘D’ above
5. Set the password of your choice.  
(The password should contain minimum 8 characters, at least one special Character (!#\$%\*), at least one numeral, at least one alphabet and at least one capital letter).
6. Enter Image Verification (CAPTCHA) Code.
7. Click “Submit” (You have now registered on InstaVote).  
Post successful registration, click on “**Login**” under ‘SHARE HOLDER’ tab & follow steps given above in points (a-b).

|                   |                              |                                                                                                                |
|-------------------|------------------------------|----------------------------------------------------------------------------------------------------------------|
| InstaVote USER ID | NSDL                         | User ID is 8 Character DP ID followed by 8 Digit Client ID (e.g.IN123456) and 8 digit Client ID (eg.12345678). |
|                   | CDSL                         | User ID is 16 Digit Beneficiary ID.                                                                            |
|                   | Shares held in physical form | User ID is Event No + Folio no., registered with the Company                                                   |

## STEP 2: Steps to cast vote for Resolutions through InstaVote

- A. Post successful authentication and redirection to InstaVote inbox page, you will be able to see the “Notification for e-voting”.
- B. Select ‘View’ icon. E-voting page will appear.
- C. Refer the Resolution description and cast your vote by selecting your desired option ‘Favour / Against’ (If you wish to view the entire Resolution details, click on the ‘View Resolution’ file link).
- D. After selecting the desired option i.e. Favour / Against, click on ‘Submit’.

- E. A confirmation box will be displayed. If you wish to confirm your vote, click on 'Yes', else to change your vote, click on 'No' and accordingly modify your vote.

NOTE: Shareholders may click on "Vote as per Proxy Advisor's Recommendation" option and view proxy advisor recommendations for each resolution before casting vote. "Vote as per Proxy Advisor's Recommendation" option provides access to expert insights during the e-Voting process. Shareholders may modify their vote before final submission.

Once you cast your vote on the resolution, you will not be allowed to modify or change it subsequently.

### **Guidelines for Institutional shareholders ("Custodian / Corporate Body/ Mutual Fund")**

#### **STEP 1 – Custodian / Corporate Body/ Mutual Fund Registration**

- A. Visit URL: <https://instavote.linkintime.co.in>
- B. Click on "Sign Up" under "Custodian / Corporate Body/ Mutual Fund"
- C. Fill up your entity details and submit the form.
- D. A declaration form and organization ID is generated and sent to the Primary contact person email ID (which is filled at the time of sign up). The said form is to be signed by the Authorised Signatory, Director, Company Secretary of the entity & stamped and sent to [insta.vote@linkintime.co.in](mailto:insta.vote@linkintime.co.in).
- E. Thereafter, Login credentials (User ID; Organisation ID; Password) is sent to Primary contact person's email ID. (You have now registered on InstaVote)

#### **STEP 2 – Investor Mapping**

- A. Visit URL: <https://instavote.linkintime.co.in> and login with InstaVote Login credentials.
- B. Click on "Investor Mapping" tab under the Menu Section
- C. Map the Investor with the following details:
  - 1) 'Investor ID' – Investor ID for NSDL demat account is 8 Character DP ID followed by 8 Digit Client ID i.e., IN000000012345678; Investor ID for CDSL demat account is 16 Digit Beneficiary ID.
  - 2) 'Investor's Name' - Enter Investor's Name as updated with DP.
  - 3) 'Investor PAN' - Enter your 10-digit PAN.
  - 4) 'Power of Attorney' - Attach Board resolution or Power of Attorney.

NOTE: File Name for the Board resolution/ Power of Attorney shall be – DP ID and Client ID or 16 Digit Beneficiary ID. Further, Custodians and Mutual Funds shall also upload specimen signatures.

- D. Click on Submit button. (The investor is now mapped with the Custodian / Corporate Body/ Mutual Fund Entity). The same can be viewed under the "Report Section".

#### **STEP 3 – Steps to cast vote for Resolutions through InstaVote**

The corporate shareholder can vote by two methods, during the remote e-voting period.

#### **METHOD 1 - VOTES ENTRY**

- a) Visit URL: <https://instavote.linkintime.co.in> and login with InstaVote Login credentials.
- b) Click on "Votes Entry" tab under the Menu section.
- c) Enter the "Event No." for which you want to cast vote.  
Event No. can be viewed on the home page of InstaVote under "On-going Events".
- d) Enter "16-digit Demat Account No.".

- e) Refer the Resolution description and cast your vote by selecting your desired option 'Favour / Against' (If you wish to view the entire Resolution details, click on the 'View Resolution' file link). After selecting the desired option i.e. Favour / Against, click on 'Submit'.
- f) A confirmation box will be displayed. If you wish to confirm your vote, click on 'Yes', else to change your vote, click on 'No' and accordingly modify your vote.  
(Once you cast your vote on the resolution, you will not be allowed to modify or change it subsequently).

## **METHOD 2 - VOTES UPLOAD**

- a) Visit URL: <https://instavote.linkintime.co.in> and login with InstaVote Login credentials.
- b) After successful login, you will see "Notification for e-voting".
- c) Select "View" icon for "Company's Name / Event number".
- d) E-voting page will appear.
- e) Download sample vote file from "Download Sample Vote File" tab.
- f) Cast your vote by selecting your desired option 'Favour / Against' in the sample vote file and upload the same under "Upload Vote File" option.
- g) Click on 'Submit'. 'Data uploaded successfully' message will be displayed.  
(Once you cast your vote on the resolution, you will not be allowed to modify or change it subsequently).

### **Helpdesk:**

#### **Shareholders holding securities in physical mode / Non-Individual Shareholders holding securities in demat mode:**

Shareholders holding securities in physical mode / Non-Individual Shareholders holding securities in demat mode facing any technical issue in login may contact INSTAVOTE helpdesk by sending a request at [enotices@in.mpms.muvg.com](mailto:enotices@in.mpms.muvg.com) or contact on: - Tel: 022 – 4918 6000.

#### **Individual Shareholders holding securities in demat mode:**

Individual Shareholders holding securities in demat mode may contact the respective helpdesk for any technical issues related to login through Depository i.e., NSDL and CDSL.

| <b>Login type</b>                                                  | <b>Helpdesk details</b>                                                                                                                                                                                                  |
|--------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Individual Shareholders holding securities in demat mode with NSDL | Members facing any technical issue in login can contact NSDL helpdesk by sending request at <a href="mailto:evoting@nsdl.co.in">evoting@nsdl.co.in</a> or call at: 022 - 4886 7000                                       |
| Individual Shareholders holding securities in demat mode with CDSL | Members facing any technical issue in login can contact CDSL helpdesk by sending request at <a href="mailto:helpdesk.evoting@cdslindia.com">helpdesk.evoting@cdslindia.com</a> or contact at toll free no. 1800 22 55 33 |

### **Forgot Password:**

#### **Shareholders holding securities in physical mode / Non-Individual Shareholders holding securities in demat mode:**

Shareholders holding securities in physical mode / Non-Individual Shareholders holding securities in demat mode have forgotten the USER ID [Login ID] or Password or both then the shareholder can use the "Forgot Password" option available on: <https://instavote.linkintime.co.in>

- Click on "**Login**" under 'SHARE HOLDER' tab.
- Click "**forgot password?**"

- Enter User ID, select Mode and Enter Image Verification code (CAPTCHA).
- Click on “SUBMIT”.

In case Custodian / Corporate Body/ Mutual Fund has forgotten the USER ID [Login ID] or Password or both then the shareholder can use the “Forgot Password” option available on: <https://instavote.linkintime.co.in>

- Click on ‘Login’ under “Custodian / Corporate Body/ Mutual Fund” tab
- Click **“forgot password?”**
- Enter User ID, Organization ID and Enter Image Verification code (CAPTCHA).
- Click on “SUBMIT”.

*In case shareholders have a valid email address, Password will be sent to his / her registered e-mail address. Shareholders can set the password of his/her choice by providing information about the particulars of the Security Question and Answer, PAN, DOB/DOI etc. The password should contain a minimum of 8 characters, at least one special character (!#\$%&\*), at least one numeral, at least one alphabet and at least one capital letter.*

**Individual Shareholders holding securities in demat mode with NSDL/ CDSL has forgotten the password:**

Individual Shareholders holding securities in demat mode have forgotten the USER ID [Login ID] or Password or both, then the Shareholders are advised to use Forget User ID and Forget Password option available at above mentioned depository/ depository participants website.

**General Instructions - Shareholders**

- ❖ It is strongly recommended not to share your password with any other person and take utmost care to keep your password confidential.
- ❖ For shareholders/ members holding shares in physical form, the details can be used only for voting on the resolutions contained in this Notice.
- ❖ During the voting period, shareholders/ members can login any number of time till they have voted on the resolution(s) for a particular “Event”.

**STATEMENT PURSUANT TO SECTION 102(1) OF THE COMPANIES ACT, 2013 READ WITH RULE 22 OF THE COMPANIES (MANAGEMENT AND ADMINISTRATION) RULES, 2014 AND ADDITIONAL INFORMATION AS REQUIRED UNDER THE SECURITIES AND EXCHANGE BOARD OF INDIA (LISTING OBLIGATIONS AND DISCLOSURE REQUIREMENTS) REGULATIONS, 2015**

**ITEM NO. 1**

In terms of Regulation 23 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“LODR Regulations”), a related party transaction to which the subsidiary of a listed entity is a party but the listed entity is not a party, shall require prior approval of the audit committee of the listed entity if the value of such transaction whether entered into individually or taken together with previous transactions during a financial year exceeds ten per cent of the annual consolidated turnover, as per the last audited financial statements of the listed entity. The annual consolidated turnover (revenue from operations) of the Company as on March 31, 2025, is INR 620.36 Crores.

The Company has a step-down subsidiary namely Espee Biopharma and Finechem LLC (“EBFL”) which expects that its transaction with Rise Pharma LLC (“RPL”), during the financial year 2025-26, will exceeds the materiality threshold as prescribed under Regulation 23 of the LODR Regulations. Hence, in line with the regulatory requirements, prior approval from shareholders by way of an Ordinary Resolution is being sought.

The Audit Committee of the Company has conducted its independent evaluation of the material terms of the proposed transaction between EBFL and RPL. After a detailed review about the proposed RPTs including rationale, material terms, justification as to why the proposed RPT(s) are in the interest of the EBFL and the Company and the basis of pricing, in the format prescribed by the SEBI vide circular dated June 26, 2025, on revised Industry Standards titled “Minimum Information to be provided to the audit committee”, the Committee has confirmed that the transaction is being executed at arm’s length and is in ordinary course of business, in complete compliance with applicable regulations and industry standards and comparable with transactions with unrelated parties. The Committee has also reviewed and taken note of the certificate placed before it, signed by the Managing Director/Chief Executive Officer and Chief Financial Officer of the Company, confirming that the terms of the proposed RPT(s) to be undertaken between EBFL and RPL are in the interest of the Company. Based on this assessment, the Audit Committee has approved the transaction for an aggregate value not exceeding INR 100 Crores (Indian Rupees One Hundred Crores) during the financial year 2025-26. The Committee further noted that the transaction price is dynamic and will be determined based on multiple commercial factors including product quality, category specifications, market conditions, type of deal and other relevant parameters. This flexible pricing mechanism ensures that the transaction remains competitive and value driven.

Details of the proposed transactions between the EBFL and RPL, including the information pursuant to Industry Standards on Related party Transactions read with applicable SEBI Circulars and applicable provisions of the Companies Act, 2013, if any, and as placed before the Audit Committee for consideration while seeking prior approval of the proposed RPT(s) and information to be placed before shareholders are provided below:

| <b>A1. Basic details of the related party</b> |                                       |                                               |
|-----------------------------------------------|---------------------------------------|-----------------------------------------------|
| <b>S. No.</b>                                 | <b>Particulars of the information</b> | <b>Information provided by the management</b> |
| 1.                                            | Name of the related party             | Rise Pharma LLC (“Rise”)                      |

| 2.                                                                 | Country of incorporation of the related party                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | United States of America                                                                                                                                                                                                                                                                                                                                                                                 |         |                       |              |    |                   |              |    |               |              |
|--------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------|-----------------------|--------------|----|-------------------|--------------|----|---------------|--------------|
| 3.                                                                 | Nature of business of the related party                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | Rise Pharma LLC is a US based DEA approved WDD service provider and pharma products distributor.                                                                                                                                                                                                                                                                                                         |         |                       |              |    |                   |              |    |               |              |
| <b>A2. Relationship and ownership of the related party</b>         |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |                                                                                                                                                                                                                                                                                                                                                                                                          |         |                       |              |    |                   |              |    |               |              |
| 1.                                                                 | <p>Relationship between the listed entity/subsidiary (in case of transaction involving the subsidiary) and the related party – including nature of its concern (financial or otherwise) and the following:</p> <ul style="list-style-type: none"> <li>• Shareholding of the listed entity/ subsidiary (in case of transaction involving the subsidiary), whether direct or indirect, in the related party.</li> <li>• Where the related party is a partnership firm or a sole proprietorship concern or a body corporate without share capital, then capital contribution, if any, made by the listed entity/ subsidiary (in case of transaction involving the subsidiary).</li> <li>• Shareholding of the related party, whether direct or indirect, in the listed entity/ subsidiary (in case of transaction involving the subsidiary).</li> </ul> | <p>EBFL does not have any direct shareholding in RPL or vice versa. However, certain promoters and shareholders of RPL hold equity interests in EBFL in their individual capacities, thereby establishing a related party relationship between the entities.</p> <p>Nil</p> <p>Not Applicable</p> <p>Nil</p>                                                                                             |         |                       |              |    |                   |              |    |               |              |
| <b>A3. Details of previous transactions with the related party</b> |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |                                                                                                                                                                                                                                                                                                                                                                                                          |         |                       |              |    |                   |              |    |               |              |
| 1.                                                                 | Total amount of all the transactions undertaken by the listed entity or subsidiary with the related party during the last financial year.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | <p>For Subsidiary</p> <table border="1"> <thead> <tr> <th>Sr. No.</th><th>Nature of Transaction</th><th>FY 2024-2025</th></tr> </thead> <tbody> <tr> <td>1.</td><td>Purchase of goods</td><td>INR 14.72 Cr</td></tr> <tr> <td>2.</td><td>Sale of goods</td><td>INR 71.98 Cr</td></tr> </tbody> </table> <p>The listed entity does not have any direct transactions with the related party i.e. Rise.</p> | Sr. No. | Nature of Transaction | FY 2024-2025 | 1. | Purchase of goods | INR 14.72 Cr | 2. | Sale of goods | INR 71.98 Cr |
| Sr. No.                                                            | Nature of Transaction                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | FY 2024-2025                                                                                                                                                                                                                                                                                                                                                                                             |         |                       |              |    |                   |              |    |               |              |
| 1.                                                                 | Purchase of goods                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | INR 14.72 Cr                                                                                                                                                                                                                                                                                                                                                                                             |         |                       |              |    |                   |              |    |               |              |
| 2.                                                                 | Sale of goods                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | INR 71.98 Cr                                                                                                                                                                                                                                                                                                                                                                                             |         |                       |              |    |                   |              |    |               |              |

|                                               |                                                                                                                                                                                                                                                                                |                                                                                                                                                        |                         |                          |
|-----------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------|--------------------------|
| 2.                                            | Total amount of all the transactions undertaken by the listed entity or subsidiary with the related party in the current financial year up to the quarter immediately preceding the quarter in which the approval is sought.                                                   | Sr. No.                                                                                                                                                | Nature of Transaction   | 01/04/2025 to 30/09/2025 |
|                                               |                                                                                                                                                                                                                                                                                | 1.                                                                                                                                                     | Purchase of goods       | INR 8.96 Cr              |
|                                               |                                                                                                                                                                                                                                                                                | 2.                                                                                                                                                     | Sale of Goods           | INR 52.68 Cr             |
| 3.                                            | Any default, if any, made by a related party concerning any obligation undertaken by it under a transaction or arrangement entered into with the listed entity or its subsidiary during the last financial year.                                                               | No defaults made                                                                                                                                       |                         |                          |
| A4. Amount of the proposed transaction(s)     |                                                                                                                                                                                                                                                                                |                                                                                                                                                        |                         |                          |
| 1.                                            | Amount of the proposed transactions being placed for approval in the meeting of the Audit Committee/ shareholders                                                                                                                                                              | Aggregate value of the related party transactions amounting to INR 100 Crores for the financial year 2025-26.                                          |                         |                          |
| 2.                                            | Whether the proposed transactions taken together with the transactions undertaken with the related party during the current financial year would render the proposed transaction a material RPT?                                                                               | Yes, after the proposed sale and purchase of goods and services, the aggregate value of proposed transaction(s) would cross the materiality threshold. |                         |                          |
| 3.                                            | Value of the proposed transactions as a percentage of the listed entity’s annual consolidated turnover for the immediately preceding financial year                                                                                                                            | 16.11%                                                                                                                                                 |                         |                          |
| 4.                                            | Value of the proposed transactions as a percentage of subsidiary’s annual standalone turnover for the immediately preceding financial year (in case of a transaction involving the subsidiary and where the listed entity is not a party to the transaction)                   | 18.49 % (of EBFL’s standalone turnover)                                                                                                                |                         |                          |
| 5.                                            | Value of the proposed transactions as a percentage of the related party’s annual consolidated turnover (if consolidated turnover is not available, calculation to be made on standalone turnover of related party) for the immediately preceding financial year, if available. | 71.80% (based on calendar year Turnover)                                                                                                               |                         |                          |
| 6.                                            | Financial performance of the related party for the immediately preceding financial year:                                                                                                                                                                                       | Particulars                                                                                                                                            | FY 2024 (Calendar Year) |                          |
|                                               |                                                                                                                                                                                                                                                                                | Turnover                                                                                                                                               | USD 16.24 million       |                          |
|                                               |                                                                                                                                                                                                                                                                                | Profit After Tax                                                                                                                                       | USD 0.062 million       |                          |
|                                               |                                                                                                                                                                                                                                                                                | Net worth                                                                                                                                              | USD 0.088 million       |                          |
| A5. Basic details of the proposed transaction |                                                                                                                                                                                                                                                                                |                                                                                                                                                        |                         |                          |



|                                                                                                                                                                           |                                                                                                                                                                                            |                                                                                                                                                                                                                                                                                                              |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 1.                                                                                                                                                                        | Specific type of the proposed transaction (e.g. sale of goods/services, purchase of goods/services, giving loan, borrowing etc.)                                                           | Sale and Purchase of goods                                                                                                                                                                                                                                                                                   |
| 2.                                                                                                                                                                        | Details of each type of the proposed transaction                                                                                                                                           |                                                                                                                                                                                                                                                                                                              |
| 3.                                                                                                                                                                        | Tenure of the proposed transaction (tenure in number of years or months to be specified)                                                                                                   | One year (For the F.Y. 2025-26)                                                                                                                                                                                                                                                                              |
| 4.                                                                                                                                                                        | Whether omnibus approval is being sought?                                                                                                                                                  | Yes                                                                                                                                                                                                                                                                                                          |
| 5.                                                                                                                                                                        | Value of the proposed transaction during a financial year. If the proposed transaction will be executed over more than one financial year, provide estimated break-up financial year-wise. | Aggregate value of the related party transactions amounting to INR 100 Crores for the financial year 2025-26                                                                                                                                                                                                 |
| 6.                                                                                                                                                                        | Justification as to why the RPTs proposed to be entered into are in the interest of the listed entity                                                                                      | Entering into transactions with RPL will enable EBFL to strengthen its global supply chain and distribution network, particularly in the regulated U.S. market. RPL being DEA approved contributes positively to the operational efficiency for EBFL and consequently, the listed entity upon consolidation. |
| 7.                                                                                                                                                                        | Details of the promoter(s)/ director(s) / key managerial personnel of the listed entity who have interest in the transaction, whether directly or indirectly                               | Not applicable                                                                                                                                                                                                                                                                                               |
|                                                                                                                                                                           | a. Name of the director / KMP                                                                                                                                                              | --                                                                                                                                                                                                                                                                                                           |
|                                                                                                                                                                           | b. Shareholding of the director / KMP, whether direct or indirect, in the related party                                                                                                    | --                                                                                                                                                                                                                                                                                                           |
| 8.                                                                                                                                                                        | A copy of the valuation or other external party report, if any, shall be placed before the Audit Committee.                                                                                | Not Applicable                                                                                                                                                                                                                                                                                               |
| 9.                                                                                                                                                                        | Other information relevant for decision making.                                                                                                                                            | Not Applicable                                                                                                                                                                                                                                                                                               |
| <b>B1. Disclosure only in case of transactions relating to sale, purchase or supply of goods or services or any other similar business transaction and trade advances</b> |                                                                                                                                                                                            |                                                                                                                                                                                                                                                                                                              |
| 1.                                                                                                                                                                        | Bidding or other process, if any, applied for choosing a party for sale, purchase or supply of goods or services.                                                                          | EBFL is already doing business with Rise.                                                                                                                                                                                                                                                                    |
| 2.                                                                                                                                                                        | Basis of determination of price.                                                                                                                                                           | Prices are determined at Arm's Length<br><br>Price of products will depend upon multiple commercial factors including product                                                                                                                                                                                |

|    |                                                                                                                                                                                                                                           |                                                                                                  |
|----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------|
|    |                                                                                                                                                                                                                                           | quality, category specifications, market conditions, type of deal and other relevant parameters. |
| 3. | In case of Trade advance (of upto 365 days or such period for which such advances are extended as per normal trade practice), if any, proposed to be extended to the related party in relation to the transaction, specify the following: | The terms and conditions as per ordinary course of business practice.                            |
|    | a. Amount of Trade advance                                                                                                                                                                                                                |                                                                                                  |
|    | b. Tenure                                                                                                                                                                                                                                 |                                                                                                  |
|    | c. Whether same is self-liquidating?                                                                                                                                                                                                      |                                                                                                  |

The Members may note that in terms of the provisions of the SEBI Listing Regulations, the related parties as defined thereunder (whether such related party is a party to the aforesaid transactions or not), shall not vote to approve resolution under Item No. 1.

None of the Directors or Key Managerial Personnel of the Company or their relatives are in any way, financially or otherwise concerned or interested in the said Resolution except to the extent of their shareholding in the Company, if any.

By order of the Board of Directors  
For & on behalf of **Remus Pharmaceuticals Limited**

**Deval Patel**  
Company Secretary & Compliance Officer  
ICSI Membership No.: A60090

**Place:** Ahmedabad

**Date:** November 10, 2025

**Registered Office:**

1101 to 1103, South Tower,  
One 42, B/H Ashok Vatika,  
Nr. Jayantilal Park BRTS,  
Ambli Bopal Road,  
Ahmedabad – 380 054, Gujarat